Abstract Number: 452 • 2014 ACR/ARHP Annual Meeting
The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis
Background/Purpose The majority of patients with established Rheumatoid arthritis (RA) have autoantibodies against the Fc of IgG (Rheumatoid factors-RhF) and to citrullinated protein antigens (ACPAs).…Abstract Number: 2356 • 2014 ACR/ARHP Annual Meeting
Toluenesulfonylamido-Chalcone, 4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC) Suppresses Inflammatory Response and Joint Destruction in an Experimental Arthritic Mice and Fibroblast-like Synoviocytes
Background/Purpose TSAHC, a toluenesulfonylamido-chalcone, 4-(p-toluenesulfonylamido)-4-hydroxychalcone is a compound to block proliferation and metastatic potential of cancer cells. Fibroblast-like synoviocytes of rheumatoid arthritis (RA-FLS) have inflammatory…Abstract Number: 940 • 2014 ACR/ARHP Annual Meeting
Reducing Therapy in Rheumatoid Arthritis Patients in Ongoing Remission
Background/Purpose: Due to improved therapeutic management a steadily increasing number of rheumatoid arthritis (RA) patients reach stable remission of disease. Data on withdrawal of medication…Abstract Number: 347 • 2014 ACR/ARHP Annual Meeting
Salt Aggravates Arthritis By Th17 Polarization
Background/Purpose Sodium chloride (NaCl) recently has been shown to drive autoimmune diseases through the induction of pathogenic interleukin 17-producing T helper (Th17) cells. This study…Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…Abstract Number: 886 • 2014 ACR/ARHP Annual Meeting
Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status?
Background/Purpose: Disease remission is the goal of treat-to-target initiatives in rheumatoid arthritis (RA). There are multiple indices to measure disease activity and remission status including…Abstract Number: 324 • 2014 ACR/ARHP Annual Meeting
Regulation of TNF-α-Mediated Activation of Rheumatoid Synovial Fibroblasts By Transcription Factor Snail
Background/Purpose: Transcription factor Snail plays active roles in various biological functions and is involved in many disease states. We hypothesized that this molecule regulates TNF-α-mediated…Abstract Number: 2340 • 2014 ACR/ARHP Annual Meeting
Human Osteoclasts Are Mobilized in Erosive Arthritis of Epstein-Barr Virus-Infected Humanized NOD/Shi-Scid/IL-2Rγnull Mice
Background/Purpose Various studies of the relationship between Epstein-Barr virus (EBV) and rheumatoid arthritis (RA) have not produced convincing evidence. Many human viruses do not infect…Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…Abstract Number: 338 • 2014 ACR/ARHP Annual Meeting
Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA.…Abstract Number: 2331 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The clinical development program for tofacitinib in RA enrolled ˃500…Abstract Number: 1726 • 2013 ACR/ARHP Annual Meeting
Survivin Inhibition Disturbs Bcl-6 and Blimp-1 Control Of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis
Background/Purpose: Survivin is a proto-oncogene known to regulate cell division and apoptosis. In patients with rheumatoid arthritis, survivin has emerged as an independent predictor of…Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…Abstract Number: L12 • 2013 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Demonstrates Efficacy and Significantly Reduces Proinflammatory Cytokines in Patients with Active Longstanding Rheumatoid Arthritis with High Gonadotropin Levels: A Proof-of-Concept, Double-Blind, Randomized Trial
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1). Inhibiting GnRH, by…Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
- « Previous Page
- 1
- …
- 178
- 179
- 180
- 181
- 182
- …
- 188
- Next Page »